Difference of cell cycle arrests induced by lidamycin in human breast cancer cells

Anti-Cancer Drugs

Volumn 17, Issue 2, 2006, Pages 173-179

  Liu, Xia ^a   He, Hongwei ^a   Feng, Yun ^a   Zhang, Min ^a   Ren, Kaihuan ^a   Shao, Rongguang ^a  

^a INSTITUTE OF MEDICINAL BIOTECHNOLOGY   (China)

Author keywords

Breast cancer cells; Cell cycle arrest; Lidamycin; p53

Indexed keywords

ANTIBIOTIC C 1027; ANTINEOPLASTIC AGENT; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; CYCLIN B1; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE INHIBITOR 1; LIDAMYCIN; MESSENGER RNA; PROTEIN P53; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL STRAIN MCF 7; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

AMINOGLYCOSIDES; ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; CDC2 PROTEIN KINASE; CELL CYCLE; CYCLIN B; CYCLIN-DEPENDENT KINASE INHIBITOR P21; ENEDIYNES; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; PHOSPHORYLATION; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; RETINOBLASTOMA PROTEIN; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33646245911     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200602000-00008     Document Type: Article

References (44)

1. Harwell LH, Weinert TA. Checkpoints: controls that ensure the order of cell cycle events. Science 1989; 246:629-634.
2. 1-S-specific cyclin-dependent kinases and by inducing p53 and p21Cip1. Cancer Res 2004; 64:9086-9092.
3. 1 checkpoint control. Cell 1995; 82:675-684.
4. 1 arrest and apoptosis in human bladder cancer T24 cells. Anticancer Res 2005; 25:971-979.
5. 2/M transition by p53. Oncogene 2001; 20:1803-1815.
6. Krause K, Wasner M, Reinhard W, Haugwitz U, Dohna CL, Mossner J, et al. The tumour suppressor protein p53 can repress transcription of cyclin B. Nucleic Acids Res 2000; 28:4410-4418.
7. Hartwell LH, Kastan MB. Cell cycle control and cancer. Science 1994; 266:1821-1828.
8. Sherr CJ. D-Type cyclins. Trends Biol Sci 1995; 20:187-190.
9. 1 control in mammalian cells. J Cell Sci 1994; 18:69-73.
10. Morgan DO. Principles of CDK regulation. Nature 1995; 374:131-134.
11. Paggi MG, Baldi A, Bonetto F, Giordano A. Retinoblastoma protein family in cell cycle and cancer: a review. J Cell Biochem 1996; 62:418-430.
12. Hiebert SW. Regions of the retinoblastoma gene product required for its interaction with the E2F transcription factor are necessary for E2 promoter repression and pRb-mediated growth suppression. Mol Cell Biol 1993; 13:3384-3391.
13. 2 checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216. Science 1997; 277:1501-1505.
14. Donzelli M, Draetta GF. Regulating mammalian checkpoints through Cdc25 inactivation. EMBO Rep 2003; 4:671-677.
15. Abraham RT. Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev 2001; 15:2177-2196.
16. Hu JL, Xue YC, Xie MY, Zhang R, Otani T, Minami Y, et al. A new macromolecular antitumor antibiotic, C-1027. I. Discovery, taxonomy of producing organism, fermentation and biological activity. J Antibiot 1988; 41:1575-1579.
17. Jiang B, Li DD, Zhen YS. Induction of apoptosis by enediyne antitumor antibiotic C1027 in HL-60 human promyelocytic leukemia cells. Biochem Biophys Res Commun 1995; 208:238-244.
18. Xu YJ, Li DD, Zhen YS. Mode of actin for C-1027, a new macromolecular antitumor antibiotic with highly potent cytotoxicity, on human BEL-7402 cells. Cancer Chemother Pharmacol 1990; 27:41-46.
19. He QY, Liang YY, Wang DS, Li DD. Characteristics of mitotic cell death induced by enediyne antibiotic lidamycin in human epithelial tumor cells. Int J Oncol 2002; 20:261-266.
20. Mchugh MM, Gawron LS, Matsui S, Beerman TA. The antitumor enediyne C-1027 alters cell cycle progression and induces chromosomal aberrations and telomere dysfunction. Cancer Res 2005; 65:5344-5351.
21. Batist G, Tulpule A, Sinha BK, Katki AG, Myers CE, Cowan KH. Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells. J Biol Chem 1986; 261:15544-15549.
22. Ogretmen B, Safa AR. Expression of the mutated p53 tumor suppressor protein and its molecular and biochemical characterization in multidrug resistant MCF-7/Adr human breast cancer cells. Oncogene 1997; 14:499-506.
23. Robinson BW, Shewach DS. Radiosensitization by gemcitabine in p53 wildtype and mutant MCF-7 breast carcinoma cell lines. Clin Cancer Res 2001; 7:2581-2589.
24. 2-M arrest. Cancer Res 2000; 60:542-545.
25. 2/M checkpoint. Anticancer Drugs 2003; 14:449-455.
26. King RW, Deshaies RJ, Peters JM, Kirschner MW. How proteolysis drives the cell cycle. Science 1996; 274:1652-1659.
27. Glotzer M, Murray AW, Kirschner MW. Cyclin is degraded by the ubiquitin pathway. Nature 1991; 349:132-138.
28. Choi YH, Lee SJ, Nguyen P, Jang JS, Lee J, Wu ML, et al. Regulation of cyclin D1 by calpain protease. J Biol Chem 1997; 272:28479-28484.
29. Melchionna R, Chen XB, Blasina A, McGowan CH. Threonine 68 is required for radiation-induced phosphorylation and activation of Cds1. Nat Cell Biol 2000; 2:762-765.
30. Zhao H, Piwnica-Worms H. ATR-mediated checkpoint pathways regulate phosphorylation and activation of human chk1. Mol Cell Biol 2001; 21:4129-4139.
31. 2/M DNA damage checkpoint. Genes Dev 2000; 14:1448-1459.
32. Fan S, El-Deiry WS, Bae I, Freeman J, Jondle D, Bhatia K, et al. P53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res 1994; 54:5824-5830.
33. Andres JL, Fan S, Turkel GJ, Wang JA, Twu NF, Yuan RQ, et al. Regulation of BRCA1 and BRCA2 expression in human breast cancer cells by DNA-damaging agents. Oncogene 1998; 16:2229-2241.
34. Connell-Crowley L, Harper JW, Goodrich DW. Cyclin D1/cdk4 regulates retinoblastoma protein-mediated cell cycle arrest by site-specific phosphorylation. Mol Biol Cell 1997; 8:287-301.
35. Nevins JR. Toward an understanding of the functional complexity of the E2F and retinoblastoma families. Cell Growth Differ 1998; 9:585-593.
36. 2/M phase cell cycle arrest involves checkpoint kinase 2-mediated phosphorylation of cell division cycle 25C. J Biol Chem 2004; 279:25813-25822.
37. 2 arrest in human cells. J Cell Biol 1996; 134:963-970.
38. 1 checkpoint in human diploid fibroblasts. Cancer Res 2000; 60:2623-2631.
39. 2 checkpoint by UCN-01 enhances ara-C-induced cytotoxicity in human colon cancer cells. Acta Pharmacol Sin 2004; 25:756-762.
40. Guo Z, Kumagai A, Wang SX, Dunphy WG. Requirement for Atr in phosphorylation of Chk1 and cell cycle regulation in response to DNA replication blocks and UV-damaged DNA in Xenopus egg extracts. Genes Dev 2000; 14:2745-2756.
41. Dziegielewski J, Beerman TA. Cellular responses to the DNA strand-scission enediyne C-1027 can be independent of ATM, ATR, and DNA-PK kinases. J Biol Chem 2002; 277:20549-20554.
42. Xu YJ, Zhen YS, Goldberg IH. C1027 chromophore, a potent new enediyne antitumor antibiotic, induces sequence-specific double-strand DNA cleavage. Biochemistry 1994; 33:5947-5954.
43. Liu JS, Kuo SR, Yin X, Beerman TA, Melendy T. DNA damage by the enediyne C-1027 results in the inhibition of DNA replication by loss of replication protein A function and activation of DNA-dependent protein kinase. Biochemistry 2001; 40:14661-14668.
44. Gottifredi V, Karni-Schmidt O, Shieh SS, Prives C. p53 down-regulates CHK1 through p21 and the retinoblastoma protein. Mol Cell Biol 2001; 21:1066-1076.